Kawasaki Disease Complicated with Macrophage Activation Syndrome: A Systematic Review

Journal of Pediatric Hematology/Oncology

Volumn 39, Issue 6, 2017, Pages 445-451

  Garciá Pavón, Susana ^a   Yamazaki Nakashimada, Marco A ^b   Baéz, Milton ^c   Borjas Aguilar, Karla L ^b   Murata, Chiharu ^b  

^a Naval Hospital of High Speciality   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c Department of Pediatric ^*  (Mexico)

Author keywords

hyperferritinemia; Kawasaki disease; macrophage activation syndrome; secondary hemophagocytic lymphohistiocytosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CYCLOSPORIN; ETOPOSIDE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUSE OF DEATH; CLINICAL FEATURE; DRUG EFFECT; FEVER; HUMAN; HYPERFERRITINEMIA; MACROPHAGE ACTIVATION SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; REVIEW; SPLENOMEGALY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; ADOLESCENT; CHILD; COMPLICATION; CORONARY VESSEL MALFORMATION; FEMALE; IMMUNOLOGY; INFANT; MALE; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ASPARTATE AMINOTRANSFERASES; CHILD; CHILD, PRESCHOOL; CORONARY VESSEL ANOMALIES; CYCLOSPORINE; ETOPOSIDE; FEMALE; FEVER; HUMANS; INFANT; MACROPHAGE ACTIVATION SYNDROME; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85020073957     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0000000000000872     Document Type: Review

References (54)

1. Atteritano M, David A, Bagnato G, et al. Haemophagocyticsyndrome in rheumatic patients. A systematic review. Eur RevMed Pharmacol Sci. 2012;10:1414-1424.
2. Al-Eid W, al-Jefri A, Bahabri S, et al. Hemophagocytosiscomplicating Kawasaki disease. Pediatr Hematol Oncol. 2000;17:323-329.
3. Latino GA, Manlhiot C, Yeung RS, et al. Macrophageactivation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol. 2010;32:527-531.
4. Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosisat initiation of Kawasaki disease and theirdifferential diagnosis. Pediatr Hematol Oncol. 2010;27:244-249.
5. Cummings C, McCarthy P, van Hoff J, et al. Kawasaki diseaseassociated with reactive hemophagocytic lymphohistiocytosis. Pediatr Infect Dis J. 2008;27:1116-1118.
6. Hendricks M, Pillay S, Davidson A, et al. Kawasaki diseasepreceding haemophagocytic lymphohistiocytosis: Challengesfor developing world practitioners. Pediatr Blood Cancer. 2010;5:1023-1025.
7. Kaneko K, Takahashi K, Fujiwara S, et al. Kawasaki diseasefollowed by haemophagocytic syndrome. Eur J Pediatr. 1998;157:610-611.
8. Ohga S, Ooshima A, Fukushige J, et al. Histiocytic haemophagocytosisin a patient with Kawasaki disease: Changes in thehypercytokinaemic state. Eur J Pediatr. 1995;154:539-541.
9. Palazzi DL, McClain KL, Kaplan SL. Hemophagocyticsyndrome after Kawasaki disease. Pediatr Infect Dis J. 2003;22:663-666.
10. Simonini G, Pagnini I, Innocenti L, et al. Macrophageactivation syndrome/hemophagocytic lymphohistiocytosisand Kawasaki disease. Pediatr Blood Cancer. 2010;55:592.
11. Titze U, Janka G, Schneider EM, et al. Hemophagocyticlymphohistiocytosis and Kawasaki disease: Combined manifestationand differential diagnosis. Pediatr Blood Cancer. 2009;53:493-495.
12. Servel AC, Vincenti M, Darras JP, et al. Intravenousimmunoglobulin resistant Kawasaki disease with hemophagocytosis. Arch Pediatr. 2012;19:741-744.
13. Suresh N, Sankar J. Macrophage activation syndrome: A rarecomplication of incomplete Kawasaki disease. Ann TropPaediatr. 2010;30:61-64.
14. Avcin T, Tse SM, Schneider R, et al. Macrophage activationsyndrome as the presenting manifestation of rheumaticdiseases in childhood. J Pediatr. 2006;148:683-686.
15. Muise A, Tallett SE, Silverman ED. Are children withKawasaki disease and prolonged fever at risk for macrophageactivation syndrome Pediatrics. 2003;112:e495-497.
16. Miettunen PM, Narendran A, Jayanthan A, et al. Successfultreatment of severe paediatric rheumatic disease-associatedmacrophage activation syndrome with interleukin-1 inhibitionfollowing conventional immunosuppressive therapy: Case serieswith 12 patients. Rheumatology (Oxford). 2011;50:417-419.
17. Shafferman A, Birmingham JD, Cron RQ. High dose anakinrafor treatment of severe neonatal Kawasaki disease: A casereport. Pediatr Rheumatol Online J. 2014;12:26.
18. Kang HR, Kwon YH, Yoo ES, et al. Clinical characteristics ofhemophagocytic lymphohistiocytosis following Kawasaki disease:differentiation from recurrent Kawasaki disease. BloodRes. 2013;48:254-257.
19. Mukherjee D, Pal P, Kundu R, et al. Macrophage activationsyndrome in Kawasaki disease. Indian Pediatr. 2014;51:148-149.
20. OgawaM, Hoshina T. Hemophagocytic lymphohistiocytosis priorto the diagnosis of Kawasaki disease. Indian Pediatr. 2015;52:78.
21. Kim HK, Kim HG, Hong YM, et al. Clinical characteristics ofhemophagocytic lymphohistiocytosis related to Kawasakidisease. Pediatr Hematol Oncol. 2011;28:230-236.
22. Wang W, Gong F, Zhu W, et al. Macrophage activationsyndrome in Kawasaki disease: More common than wethought Semin Arthritis Rheum. 2015;44:405-410.
23. Bose K, Saha S, Saha P, et al. Macrophage activation syndrome: Apotentially fatal complication of Kawasaki disease. Arch Rheumatol. 2015;30:178-180. doi: 10. 5606/ArchRheumatol. 2015. 5186.
24. Thabet F, Bellara I, Tabarki B, et al. Ischemic colitis andhemophagocytosis complicating Kawasaki disease. Arch Pediatr. 2004;11:226-228.
25. Park HJ, Cho YJ, Bae EY, et al. Macrophage activationsyndrome as the extreme form of Kawasaki disease. Korean JPediatr Infect Dis. 2010;17:177-181.
26. Liu RH, Liu HL. Kawasaki disease complicated by autoinmunehemolytic anemia and macrophage activation syndrome: A casereport. Zhongguo Dang Dai Er Ke Za Zhi. 2009;11:778-779.
27. Hu XF, Wang HW, Shi H. Macrophage activation syndromein 2 cases with Kawasaki disease: Clinical analysis and review ofliterature. Zhonghua Er Ke Za Zhi. 2006;44:833-835.
28. Yun HJ, Kim HM, Park SW, et al. Hemophagocytic syndromewith Kawasaki disease and peripheral gangrene. Korean JPediatr. 2002;45:664-668.
29. Inoue S, Mangat C, Rafe Y, et al. Forme Fruste of HLH(haemophagocytic lymphohistiocytosis): Diagnostic and therapeuticchallenges. BMJ Case Rep. 2015;2015:bcr2014206190. doi:10. 1136/bcr-2014-206190.
30. Oflaz Sozmen B, Kebudi R, Dindar A, et al. A case ofsecondary hemophagocytic lymphohistiocytosis (HLH) followingincomplete Kawasaki's disease (KD). Importance ofdistinguishing recurrent KD from HLH. Pediatr Blood Cancer. Conference: 46th Congress of The International Society ofPaediatric Oncology 2014: S297.
31. Dapul-Hidalgo G, Li W, Moallem J. Fever, rash, arthritis in a7 year old girl with macrophage activation syndrome. AnnAllergy Asthma Immunol. 2010;105:A62 Nov 2010.
32. Dogan V, Karaaslan E, Ö zer S, et al. Hemophagocytosis in theacute phase of fatal Kawasaki disease in a 4 month-old girl. Balkan Med J. 2016;33:470-472.
33. Kato S, Yoshimura K, Tanabe Y, et al. A child with Epstein-Barr Virus-associated hemophagocytic lymphohistiocytosiscomplicated by coronary artery lesion mimicking Kawasakidisease. J Pediatr Hematol Oncol. 2013;35:e317-e319.
34. Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminarydiagnostic guidelines for macrophage activation syndromecomplicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598-604.
35. Ravelli A, Minoia F, Davi S, et al. 2016 Classification criteriafor macrophage activation syndrome complicating systemicjuvenile idiopathic arthritis: A European league againstrheumatism/American College of Rheumatology/PaediatricRheumatology International Trials Organisation CollaborativeInitiative. Ann Rheum Dis. 2016;75:481-489.
36. Han SB, Lee SY, Jeong DC, et al. Should 2016 Criteria forMacrophage Activation Syndrome be applied in children withKawasaki disease, as well as with systemic-onset juvenileidiopathic arthritis Ann Rheum Dis. 2016;75:e44.
37. Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) andrelated disorders. Hematology (Am Soc Hematol Educ Program). 2009;1:127-131. doi: 10. 1182/asheducation-2009. 1. 127.
38. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnosticand therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-131.
39. Ishii E. Hemophagocytic lymphohistiocytosis in children:pathogenesis and treatment. Front Pediatr. 2016;4:47.
40. Chen X, Zhao ZW, Li L, et al. Hypercoagulation and elevationof blood triglycerides are characteristics of Kawasaki disease. Lipids Health Dis. 2015;14:166.
41. Choi UY, Han SB, Lee SY. Should refractory Kawasakidisease be considered occult macrophage activation syndromeSemin Arthritis Rheum. 2017;46:e17.
42. Nasir A, Al Tatari H, Hamdan MA. Very high serum ferritinlevels in three newborns with Kawasaki-like illness. PaediatrChild Health. 2012;17:201-204.
43. Nofech-Mozes Y, Garty BZ. Thrombocytopenia in Kawasakidisease: A risk factor for the development of coronary arteryaneurysms. Pediatr Hematol Oncol. 2003;20:597-601.
44. Villanueva J, Lee S, Giannini EH, et al. Natural killer celldysfuntion is a distinguishing feature of systemic onset juvenilerheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7:30-37.
45. Zhang K, Biroschak J, Glass DN, et al. Macrophage activationsyndrome in patients with systemic juvenile idiopathic arthritisis associated with MUNC13-4 polymorphisms. Rheumatology(Oxford). 2010;49:441-449.
46. Vastert SJ, van Wijk R, D'Urbano LE, et al. Mutations in theperforin gene can be linked to macrophage activationsyndrome in patients with systemic onset juvenile idiopathicarthritis. Ann Rheum Dis. 2016;75:481-489.
47. Guzman-Cottrill JA, Garcia FL, Shulman ST, et al. CD8 Tlymphocytes do not express cytotoxic proteins in coronaryartery aneurysms in acute Kawasaki disease. Pediatr Infect DisJ. 2005;24:382-384.
48. Ge X, Li CR, Yang J, et al. Aberrantly decreased levels ofNKG2D expression in children with Kawasaki disease. Scand JImmunol. 2013;77:389-397.
49. Campbell AJ, Burns JC. Adjunctive therapies for Kawasakidisease. J Infect. 2016;72 Suppl:S1-S5.
50. Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemiain the critically ill child with secondary hemophagocyticlymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatmentCrit Care. 2012;16:R52.
51. Hokosaki T, Mori M, Nishizawa T, et al. Long-term efficacyof plasma exchange treatment for refractory Kawasaki disease. Pediatr Int. 2012;54:99-103.
52. Hamada H, Suzuki H, Abe J, et al. Inflammatory cytokineprofiles during cyclosporin treatment for immunoglobulinresistantKawasaki disease. Cytokine. 2012;60:681-685.
53. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A inthe treatment of macrophage activation syndrome in juvenilearthritis: Report of five cases. J Pediatr. 1996;129:750-754.
54. Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role ofanakinra, an interleukin-1 receptor antagonist, in the managementof secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndromein critically ill children. Pediatr Crit Care Med. 2014;15:401-408.